<DOC>
	<DOCNO>NCT01339026</DOCNO>
	<brief_summary>Patients admit hospital chest pain due reduce blood flow heart muscle ( diagnosis Acute Coronary Syndrome ) treat medication angioplasty ± stent procedure , restore blood flow heart . Antiplatelet drug ( Aspirin Clopidogrel ) blood thin treatment research report reduce heart attack , death stroke . The investigator know patient respond fully Clopidogrel currently patient test . The investigator wish perform trial identify patient respond fully Clopidogrel randomise either Prasugrel ( new drug ) high dose Clopidogrel . Patients admitted hospital ( 2 UK 1 Germany ) ask consent participate . A blood sample test platelet activity . 1 . Low platelet activity result mean patient respond well Clopidogrel continue routine dose . They enter observational registry . Data collect routine blood test investigation , medication procedure . Their GP contact 30 day see alive . 2 . High platelet activity result mean patient respond fully Clopidogrel . These patient randomly allocate high dose Clopidogrel new drug Prasugrel . Data collect routine blood test investigation , medication procedure . A hospital visit 30±5 day require assess patient , medication occurrence event .</brief_summary>
	<brief_title>Evaluating Additional Platelet Inhibition Patients With High Platelet Reactivity Undergoing Percutaneous Coronary Intervention</brief_title>
	<detailed_description>STUDY DESCRIPTION This multinational , randomise open label study compare Prasugrel versus Clopidogrel ACS patient high platelet reactivity manage early invasive strategy ( PCI early possible later 72 hour admission ) . Patients identify low platelet reactivity indicate good response Clopidogrel enter observational Registry . Sites There three participate hospital , two UK one Germany . Screening All patient admit hospital suspect ACS require early PCI ( within 3 day admission ) screen entry trial . The investigator and/or his/her designee explain study requirement procedures obtain consent study procedure perform . We estimate approximately 500 patient screen . From total 140 patient randomised , remain screened patient enter registry . There competitive recruitment site expect randomise 40 50 patient . We estimate 7 8 patient randomise per month period 18 month . Routine blood test investigation carry accord local management strategy . The angiogram PCI procedure part routine management patient perform accord local policy procedure . A research blood sample required determine platelet activity take &gt; 2hours standard Clopidogrel pre-PCI loading . For patient take catheter laboratory around PCI procedure . In patient load Clopidogrel close PCI procedure blood sample may take ward recovery area . Depending platelet activity result patient either enter registry randomly allocate either Clopidogrel Prasugrel . 1 . Patients good responder Clopidogrel ( platelet reactivity &lt; 400 AUC min ) enter registry . 2 . Patients poor responder Clopidogrel ( platelet reactivity &gt; 400AUC min ) randomise . REGISTRY PATIENTS Patients continue standard treatment Clopidogrel . Data collect routine blood test investigation , medication procedure . Additional blood sample take ( patient consent ) biomarker genetic sub-studies . Their GP contact 30±5 day see alive . RANDOMISED PATIENTS Randomisation Investigators access automate telephone automate web service . Investigators confirm patient fulfils eligibility criteria consent obtain . Randomised Treatment Randomised patient allocate receive either open label Clopidogrel ( Plavix ) Prasugrel ( Efient ) . Group 1 : Clopidogrel ( Plavix ) - Day 1 Loading 600mg - Day 2 7 day : 150mg o.d . - Day 8 30±5 day : 75mg o.d . Group 2 : Prasugrel ( Efient ) - Day 1 load 60mg - Day 2 7 10mg o.d . - Day 8 30±5 day 10mg od Drug Supply Storage Prasugrel , commercially available product , supply Eli Lilly hold manufacture license produce Prasugrel . Clopidogrel ( Plavix ) purchase hospital Pharmacy normal purchasing arrangement . All study drug store appropriate locked room , control Hospital Pharmacist Investigator , condition describe package insert . Hospital Admission Discharge - Patients follow discharged home . - Blood sample take platelet activity 1 , 4 24 hour , pre-discharge . - Blood sample biomarker substudy take pre-PCI procedure 24 hour discharge . - Blood sample genetic substudy take baseline possible pre-discharge . - Patients instruction contact research team question concern . One Month Follow UP RCT Patients RCT require attend hospital follow visit 30±5 day date randomisation . Patients assess investigator his/her designee heart rate blood pressure , medication tolerance compliance , occurrence adverse event clinical endpoint , blood sample platelet activity . At time investigator discuss patient treatment option period . Sub-studies There two sub-studies propose ( ) biomarker ( ii ) genetic . Blood sample take store locally shipment core lab Germany .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>1 . ACS patient intent PCI &lt; 72 hour admission . 2 . Prior clopidogrel load within 24h plan PCI chronic ( &gt; 24 hour ) treatment clopidogrel 3 . High platelet reactivity ( HPR ) PA &gt; 400 AU min multiplate analyser ( `` poor responder '' ) 4 . Initial platelet function sample least 2 hour pre PCI load dose 5 . Consent 1 . Patients &lt; 18 year &gt; 75 year 2 . Body weight &lt; 60kg 3 . Pretreatment prasugrel within 7 day randomisation 4 . History stroke transient ischaemic attack 5 . Patients increase bleed risk e.g . recent major trauma surgery gastrointestinal bleeding active peptic ulceration Platelet count &lt; 100,000 / mm3 time screen Internationally Normalized Ratio ( INR ) &gt; 1.5 time screen 6 . Hb &lt; 10g/dL 7 . Intracranial neoplasm , arteriovenous malformation aneurysm . 8 . Severe hepatic impairment ( Child Pugh class C ) 9 . Intention use follow medication oral anticoagulation antiplatelet therapy ( include GPIIb/IIIa inhibitor ) besides aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) cyclooxygenase2 ( COX2 ) inhibitors 10 . Female patient pregnant , planning pregnancy , use reliable contraception breastfeed 11 . Known allergy , hypersensitivity contraindication prasugrel clopidogrel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Acute coronary syndrome</keyword>
	<keyword>Platelet reactivity</keyword>
	<keyword>Clopidogrel</keyword>
	<keyword>Percutaneous coronary intervention</keyword>
</DOC>